Abstract: Immunotherapy, particularly lung cancer vaccine therapy, has advantages of less side effects and low costs over classi -cal therapies of lung cancer, such as surgery, radiotherapy, and chemotherapy, as well as the relatively new molecular targeting therapy. PhaseⅢclinical trial for many kinds of non-small cell lung cancer (NSCLC) vaccines is ongoing based on deeper understanding of im -mune system and the expression of tumor antigens. This review summarizes the development of NSCLC vaccines.